Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator modulator treatment for people living with cystic fibrosis ages 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex non-opioid pain drug picked up by UnitedHealth
- Vertex Pharmaceuticals: Buy Rating Driven by Outpatient Market Potential and Strategic Initiatives for Journavx
- Goldman Sachs starts Sionna Therapeutics with Early-Stage Biotech designation
- Vertex Pharmaceuticals gets CHMP opinion recommending Kaftrio label expansion
- Vertex Pharmaceuticals upgraded to Buy from Hold at Erste Group